ArticleThe Journal of experimental medicine2000
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
Article in The Journal of experimental medicine, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 88 citations in OpenAlex.
- Development of Human Cell-BasedFrontiers in cellular and infection microbiology · 2022Article
- System-Level Scenarios for the Elucidation of T Cell-Mediated Germinal Center B Cell Differentiation.Frontiers in immunology · 2021Review
- Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel Multiple Sclerosis Risk Genes.Frontiers in neuroscience · 2021Article
- Synergy between B cell receptor/antigen uptake and MHCII peptide editing relies on HLA-DO tuning.Scientific reports · 2019Article
- Class II MHC antigen processing in immune tolerance and inflammation.Immunogenetics · 2019Review
- HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.Molecular & cellular proteomics : MCP · 2019Article
- Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.Nature communications · 2018Article
- Human leukocyte Antigen-DM polymorphisms in autoimmune diseases.Open biology · 2016Review
- pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity.Scientific reports · 2015Article
- MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.Cold Spring Harbor perspectives in biology · 2013Review
- HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.Nature structural & molecular biology · 2013Article
- Article
- Article
- Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.The Journal of biological chemistry · 2010Article
- Article
- Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.Haematologica · 2010Article
- Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta.Immunology · 2009Article
- MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes.Experimental and molecular pathology · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed in B cells and impedes the activity of DM, yet its physiological role remains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility complex class II-eluted peptides show that DO affects the antigenic peptide repertoire of class II. DO generates both quantitative and qualitative differences, and inhibits presentation of large-sized peptides. DO function was investigated under various pH conditions in in vitro peptide exchange assays and in antigen presentation assays using DO(-) and DO(+) transfectant cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway was prevented with bafilomycin A(1), an inhibitor of vacuolar ATPases. DO effectively inhibits antigen presentation of peptides that are loaded onto class II in endosomal compartments that are not very acidic. Thus, DO appears to be a unique, cell type-specific modulator mastering the class II-mediated immune response induced by B cells. DO may serve to increase the threshold for nonspecific B cell activation, restricting class II-peptide binding to late endosomal compartments, thereby affecting the peptide repertoire.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.